Navigation Links
Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
Date:5/12/2009

Pharma's Premier Quantitative Company and Drug Evaluation Tool Designed Specifically for Business Development Available Now with a New User-Friendly Interface

Productview Plus from Decision Resources Includes Data for Over 1000 Drugs Across 147 Product Classes

WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the growth in drug sales of the top 10 pharmaceutical companies slowed to its lowest level in years in 2008 -- growing just 3.7 percent compared to 7.9 percent the year before. The performance of the top 10 companies in the U.S. market, the world's largest, was particularly poor, with sales down 3.5 percent year-over-year.

"This trend is expected to continue in the U.S. with growth in the top 10 companies forecasted to remain flat out to 2015 despite the contribution of recently seen large-scale acquisitions by Pfizer, Roche and Merck & Co.," said Stephan Gauldie Ph.D., Director at Decision Resources. "Of the top 10 pharma companies, only Roche is expected to post a compound annual growth rate above the 3 percent that is forecasted for the overall U.S. market out to 2015."

These data come from the newly updated Productview Plus, the pharmaceutical industry's premier quantitative company and drug evaluation tool designed specifically for business development. The new Productview Plus allows business planners and new product commercialization managers to quickly assess forecasts and evaluate market scenarios that will determine a company's/drug's success or failure.

"By manipulating the data by brand, therapeutic area, drug class and company, users can track market sizes, assess barriers to market entry, quickly benchmark internal forecasts or analyze the potential of licensing candidates," continued Dr. Gauldie.

Based on company reported sales, Productview Plus includes data for 1,100 ethical drugs from over 110 companies and across 147 product classes. Productview Plus provides five years of historical sales as well as a seven-year forecast for all drugs, split by United States and Rest of World regions -- allowing users to get a universal understanding of a company's/drug's current and future position.

Productview Plus is available now from Decision Resources.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Elizabeth Marshall
    Decision Resources
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Actuaries: Addressing Health Spending Growth is Path to Sustainable Health Care System
2. Covance To Present at Bairds 2009 Growth Stock Conference
3. Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results
4. Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine
5. AMN Healthcare Services to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference and at the Robert W. Baird 2009 Growth Stock Conference
6. Adolescent Growth Plate Injuries May Be Related to Overuse
7. Despite the Economic Downturn, Long-Term Growth Potential in the US Dental Biomaterial Market Remains Robust
8. Process controlling T cell growth and production identified
9. Injured Marines at Risk for Abnormal Bone Growth
10. Injured Marines at risk for abnormal bone growth
11. Genoptix Reports Strong Growth for the First Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology: